Efficacy and safety of atazanavir in patients with end-stage liver disease

Infection

Volumn 37, Issue 3, 2009, Pages 250-255

  Guaraldi, G ^a   Cocchi, S ^a   Motta, A ^a   Ciaffi, S ^a   Codeluppi, M ^a   Bonora, S ^b   Di Benedetto, F ^a   Masetti, M ^a   Floridia, M ^c   Baroncelli, S ^c   Pinetti, D ^a   Bertolini, A ^a   Gerunda, G E ^a   Esposito, R ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ATAZANAVIR; BILIRUBIN; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; LAMIVUDINE PLUS TENOFOVIR; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OLIGOPEPTIDE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; BRAIN HEMORRHAGE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PILOT STUDY; PRACTICE GUIDELINE; THERAPY EFFECT; TRANSPLANTATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CHRONIC KIDNEY FAILURE; FOLLOW UP; IMMUNOLOGY; LIVER FUNCTION TEST; MIDDLE AGED; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OLIGOPEPTIDES; PILOT PROJECTS; PYRIDINES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 67650261003     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-8025-z     Document Type: Article

References (16)

1. S.C. Darby D.W. Ewart P.L. Giangrande R.J. Spooner C.R. Rizza G.M. Dusheiko C.A. Lee C.A. Ludlam F.E. Preston 1997 Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation Lancet 350 1425 1431
2. B. Soto A. Sanchez-Quijano L. Rodrigo J.A. del Olmo M. Garcia-Bengoechea J. Hernandez-Quero C. Rey M.A. Abad M. Rodriguez M. Sales Gilabert F. Gonzalez P. Miron A. Caruz F. Relimpio R. Torronteras M. Leal E. Lissen 1997 Human immunodeficiency virus infection modifies the natural history of chronic parenterallyacquired hepatitis C with an unusually rapid progression to cirrhosis J Hepatol 26 1 5
3. P.T. Telfer D. Brown H. Devereux C.A. Lee G.M. DuSheiko 1994 HCV RNA levels and HIV infection: evidence for a viral interaction in haemophilic patients Br J Haematol 88 397 399
4. I. Bica B. McGovern R. Dhar D. Stone K. McGowan R. Scheib D.R. Snydman 2001 Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection Clin Infect Dis 32 492 497
5. V. Soriano J. Garcia-Samaniego E. Valencia R. Rodriguez-Rosado F. Munoz J. Gonzalez-Lahoz 1999 Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users Eur J Epidemiol 15 1 4
6. P. Cacoub L. Geffray E. Rosenthal C. Perronne P. Veyssier G. Raguin 2001 Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997 Clin Infect Dis 32 1207 1214
7. L. Martin-Carbonero V. Soriano E. Valencia J. Garcia-Samaniego M. Lopez J. Gonzalez-Lahoz 2001 Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients AIDS Res Hum Retroviruses 17 1467 1471
8. M. Puoti A. Spinetti A. Ghezzi F. Donato S. Zaltron V. Putzolu E. Quiros-Roldan B. Zanini S. Casari G. Carosi 2000 Mortality for liver disease in patients with HIV infection: a cohort study J Acquir Immune Defic Syndr 24 211 217
9. D.L. Wyles J.G. Gerber 2005 Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction Clin Infect Dis 40 174 181
10. The Panel on Clinical Practices for Treatment of HIV infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (29 Jan 2008). Available at: http://aidsinfo.nih.gov/Guidelines. Accessed 23 Feb 2008.
11. C. Aube F. Oberti N. Korali M.A. Namour D. Loisel J.Y. Tanguy E. Valsesia C. Pilette M.C. Rousselet P. Bedossa H. Rifflet M.Y. Maiga D. Penneau-Fontbonne C. Caron P. Cales 1999 Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis J Hepatol 30 472 478
12. A. Colli M. Fraquelli M. Andreoletti B. Marino E. Zuccoli D. Conte 2003 Severe liver fibrosis or cirrhosis: accuracy of US for detection-analysis of 300 cases Radiology 227 89 94
13. A. Di Lelio C. Cestari A. Lomazzi L. Beretta 1989 Cirrhosis: diagnosis with sonographic study of the liver surface Radiology 172 389 392
14. Kaul S, Bassi K, Damle B, Xie J, Gale J, Kearne B, Hanna. Abstract 43rd Interscience Conf Antimicrobial Agents Chemotherapy. Abstract A-1616 2003.
15. Cahn P, Piliero P, Giordano M, Thiry A, Schnitman S. Abstract 42nd Interscience Conf Antimicrobial Agents Chemotherapy. Abstract H-1730 2002.
16. Brouwer KLR, Dukes GE, Powell JR: Influence of liver function on drug disposition. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics, principles of therapeutic drug monitoring. 3rd edition Appl Therapeutics, Vancouver 1992, pp 6.1-6.59.